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ABSTRACT 
 
Introduction : In India, colorectal cancer is the 6th most prevalent cancer and population based time trend studies 
show a rising trend in its incidence. CEA is expressed in significant amounts post-natally by the carcinomas arising 
from large intestine. Currently, the most useful application of CEA is in the detection of liver metastasis from 
colorectal cancers and serial determination of CEA is recommended for detecting cancer spread to the liver. Aim: 
To assess the role of CEA in the management of colorectal cancer, and detection of early recurrence. Methods and 
Material: 30 patients with colorectal cancer admitted in Vydehi Institute of Medical Sciences & Research Centre 
during the period of November 2012 to April 2014 were included in a prospective study. Statistical analysis used: 
Descriptive statistics were calculated for all variables. Analysis was performed using the SPSS 14.0 statistical 
package. Results: Total  patients included in the study was 30. The mean age at presentation was 48.66yrs. The most 
common site of malignancy was rectum (46.66%), and most of the patients presented in stage I. Pre-operatively 
CEA was raised in 22 cases. On postoperative follow-up, CEA was found to be elevated in 7 cases. 6 out of these 
cases had proven recurrence. One case was found to have peritoneal deposit in spite of CEA levels being normal. 
The sensitivity and specificity of using CEA as an indicator for recurrence were 85.71% and 95.65% respectively. 
Conclusions: Since colorectal cancer is associated with considerable morbidity and mortality, early diagnosis and 
management provide a chance for better survival. The use of CEA as an early indicator for recurrence has been 
evaluated in this study and can be used for the same. However, a larger size and longer duration of study is needed 
to effectively prove the same. 
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Introduction 
 
 
Colorectal cancer is the third most commonly 
diagnosed cancer in males and the second in females, 
with over 1.2 million new cancer cases and 608,700 
deaths estimated to have occurred in 2008. The highest 
incidence rates are found in Australia and New 
Zealand, Europe, and North America, whereas the 
lowest rates are found in Africa and South-Central Asia 
[1]. Incidence rates have been decreasing for most of 
the past two decades owing to the use of colorectal 
cancer screening tests that allow the detection and  
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removal of colorectal polyps before they progress to 
cancer. [2]. Human neoplasms may produce and 
release into circulation a variety of substances 
collectively called as tumour markers. The oncofetal 
antigens comprise one particular group of markers, of 
which the carcinoembryogenic antigen (CEA) has been 
most widely studied[3].CEA was first described more 
than three decades ago by Gold and Freedman when 
they identified an antigen that was present in both fetal 
colon and colon adenocarcinoma but appeared to be 
absent from healthy adults[4].This antigen is a 
glycoprotein of about 200,000 molecular size, absent 
from normal adult intestinal mucosa but present in 
primitive endoderm. It was, therefore, called 
carcinoembryonic antigen (CEA) [3, 5].In cancer 
localized to the mucosa and submucosa, the percentage 
of patients with an elevated test is between 30% and 
40%. Therefore, the use of CEA as a screening 
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technique for the asymptomatic population cannot be 
justified [5].Levels of CEA can be applied usefully in 
assessing the prognosis of individuals with colorectal 
cancer. If the tumor has been completely excised, any 
elevated level preoperatively should return to normal 
within a few days. A limited fall to an intermediate, 
albeit elevated, level is indicative of incomplete 
excision. Subsequent elevation after return to normal 
implies recurrence of tumor. This is true not only after 
resection of the primary cancer but also after resection 
for recurrent tumor. [5] 
Specifically, by determining preoperative and 
postoperative CEA levels, one can identify patients in a 
poorer prognostic group who may benefit from early 
introduction of adjuvant therapy[5].The preoperative 
CEA level also has some prognostic significance. 
Patients with localized disease have a higher recurrence 
rate when preoperative CEA is high, than when the 
level is low. Such an elevation may be suggestive of 
unapparent spread of the tumor. This suggests 
undetected disseminated disease hence poorer 
prognosis[5].There is also a relationship between the 
preoperative CEA level and the depth of invasion 
according to Dukes' classification and tumor fixation.In 
contrast, Sener and colleagues showed, that the 
preoperative CEA level can be an indicator of survival 
that is independent of the stage of disease[5]. 
 
Factors affecting serum CEA concentrations in 
patients with Colorectal cancer.  
Tumour stage –Both the concentration and proportion 
of patients with increased values tend to increase with 
increasing disease stage [6] 
Tumour Grade – Well-differentiated colorectal 
cancers produce more CEA per gram of total protein 
than poorly differentiated specimens. A lack of 
differentiation or poor differentiation may explain why 
some patients with advanced colorectal cancer do not 
have increased serum CEA values [6] 
Liver Status – The liver is the primary site for the 
metabolism of CEA. Impaired liver function affects the 
clearance of CEA, consequently increasing its serum 
levels [6] 
Tumour site within the colon – Patients with tumours 
in the left side generally have a higher incidence of 
increased CEA concentrations than those with 
malignancies on right side of the colon [6] 
CEA as a marker for Colorectal Cancer. 
Screening – In screening for colorectal cancer, the aim 
should be to detect disease at an early stage. Using 
2.5ng/dl as an upper limit, Fletcher calculated that 
CEA has a sensitivity of 36% and specificity of 87% in 
screening stage I and II cancers. These findings, 
combined with the low prevalence of this malignancy 
in unselected populations, render the positive 
predictive value of CEA unacceptably low and thus of 
little value in screening healthy subjects [6]. 
Diagnosis- Lack of sensitivity and specificity limit the 
application of CEA in diagnosing colorectal cancer, 
especially in early disease. Regarding specificity, it 
must be mentioned that CEA can be increased in most 
types of advanced adenocarcinomas as well as in 
multiple benign disorders. However, in patients with 
appropriate symptoms, highly increased concentration 
should be considered strongly suggestive for the 
presence of cancer in that particular patient [6]. 
Assessing Prognosis – Although less work has been 
carried out to investigate the prognostic value of 
postoperative CEA concentrations, the available 
evidence suggests that high concentrations at this time 
also predict adverse outcomes. Failure of an increased 
pre-operative value to decrease to normal 
concentrations within six weeks of surgery frequently 
is associated with early recurrent disease [6]. 
Surveillance – The aim of CEA monitoring after 
curative resection of colorectal cancer is to detect 
recurrent disease at an early and treatable stage. 
Longitudinal CEA measurements detect recurrent 
cancer with a sensitivity of 80% and specificity of 
70%. The wide ranges of sensitivities and specificities 
are likely to be attributable to factors such as frequency 
of CEA assay and definition of a CEA increase [6]. 
Serial CEA determinations are most useful in detecting 
liver metastasis. In a prospective study of 305 patients, 
Arnould et al showed that increases CEA 
concentrations had a sensitivity of 94% and specificity 
of 96% in detecting liver metastasis. In another 
prospective evaluation CEA was reported to have 
100% sensitivity in detecting liver metastasis [6].It 
appears to be the most cost effective test for the 
detection of potentially curable recurrent disease. [6] 
Aim: To assess the role of CEA in the management of 
colorectal cancer in our institution. 
Methodology: 30 patients with colorectal cancer 
admitted in Vydehi Institute of Medical Sciences and 
Research Centre, Bangalore during the period 
November 2012 to April 2013 were included in this 
study. Patients were followed up postoperatively for a 
period of 6 months for recurrence with evaluation of 
CEA. 
Inclusion Criteria: Cases diagnosed as colorectal 
cancer, operated and diagnosis confirmed with histo-
pathological examination. 
Exclusion Criteria: Inoperable cases of colorectal 
cancer.  
Data was recorded in a specifically designed proforma 
pertaining to patient particulars, history, clinical 
examinations, investigations (including serum CEA 
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levels), surgical procedures and follow- up. The 
decision of type of surgery was taken depending on the 
location of the tumour. Patients with malignancies in 
higher stage was subjected to adjuvant chemotherapy. 
All the patients were followed up at 3 months and then 
at 6 months. Patients were evaluated with serum CEA 
levels and various imaging studies. Those cases which 
were diagnosed to have recurrence and metastasis were 
further managed with curative resection, chemotherapy 
and radiation therapy.  
 
Result 
 
The maximum no. of cases was males having a 
percentage of 56.66% as compared to females with a 
percentage of 43.33%. The maximum no. of cases 
among males ranged in the age group 50-59 (35.29%). 
Maximum no. of cases among females were in the age 
group of 40-49 (38.46%). 
Both sexes put together had majority of cases in the 
age group of 40-59 (60%). 
The youngest patient was noted to be in the age group 
of 20-29. It was found that colorectal cancer is 
predominantly a disease of middle and old age group. 
Out of the 30 cases, 22 patients had elevated CEA 
levels pre-operatively, a percentage of 77.33%. Cut off 
value for elevation of CEA was taken as 5ng/dl. 
Factors affecting CEA 
I. Stage of tumour. 
We found that there is an increase in proportion of 
patients having elevated levels of CEA with increase in 
the disease stage. Stage I had 56.23% of patients with 
elevated CEA level, stage II had 75% and Stage III had 
100%.With respect to Duke’s staging, none of the 
cases with Duke’s Stage A had elevated CEA, 64.28% 
with Stage B1 had elevated CEA followed by 75% 
with B2 and 100% with C1 and C2 had elevated CEA.  
II. Grade of tumour 
Mean concentrations of CEA were found to be higher 
with better differentiation of the tumour. Well 
differentiated carcinomas had a mean concentration of 
16.9ng/dl, moderately differentiated carcinoma had 
10.63ng/dl and poorly differentiated carcinoma had 
4.85ng/dl. 
III. Side of tumour 
Incidence of raised CEA levels were higher in 
colorectal cancer occurring on the left side(59.0%) in 
comparison to those on the right side (40.9%). Total 
number of patients with raised pre-operative CEA 
levels were 22 out of which 9 cases were that of right 
side and 13 were that of left side. 
CEA LEVELS IN FOLLOW-UP PERIOD 
We observed that that there was no rise in CEA levels 
during the first month follow up. During the 6th month 
follow-up, 8 out of 30 patients had increase in CEA 
levels (26.66%). 
Pre-operative levels of CEA 
 Total no. of patients in the study - 30  
 Total no. of patients with raised CEA – 22 
 Percentage – 73.33% 
 
Table 1: Statistical analysis of pre-operative CEA 1 
 
Table 2: Statistical analysis of pre-operative CEA 2 
 
 
 
 
Post-operative levels of CEA (follow-up within 6 months) 
 
  Total no. of patients in the study -30 
  Total no. of patients with raised CEA levels on follow up – 7 
  Total no. of patients who were proven to have recurrences in the follow-up period by imaging studies – 7  
 
 
TRUE POSITIVE (patients with increased levels of CEA and those who had colorectal cancer
  
22 
TRUE NEGATIVE (patients without elevation of CEA and did not have colorectal cancer                                                                                                               0  
 FALSE POSITIVE (patients who had elevated levels of CEA but did not have colorectal 
cancer )                                                                                       
0 
 FALSE NEGATIVE (patients without elevation of CEA and had colorectal cancer) 8 
Sensitivity  73.33% 
Positive predictive value    100% 
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Table 3: Statistical analysis of post-operative CEA 1 
 
True positives (patients with raised levels of CEA with proven recurrence)         6 
False positive (patients with elevated CEA without recurrence) 1 
True negatives (patients without elevated CEA) 22 
False negative (patients without elevation of CEA and with proven recurrence)  1 
 
Table 4: Statistical analysis of post operative CEA 2 
 
 
 
 
 
 
 
Discussion 
 
This was a prospective clinical study conducted on 30 
cases of colorectal cancer and the role of the tumour 
marker Carcinoembryogenic Antigen in the 
management of the disease. The maximum no. of cases 
were males having a percentage of 56.66% as 
compared to females with a percentage of 43.33%. 
Both sexes put together had majority of cases in the 
age group of 40-59, having a percentage of 60%.Serum 
CEA was found to be elevated in 77.33% of cases at 
diagnosis. Serum CEA levels are found to depend on 
the site of tumour, the stage of the disease and the 
pathological grade of adenocarcinoma. Incidence of 
raised CEA levels were higher in left sided tumours 
(59%) when compared to right sided tumours 
(40.9%).CEA levels were found to be higher in patients 
with increased stage of the disease. 100% of cases in 
stage IIIA and stage IIIB of TNM staging system were 
found to have raised CEA levels, whereas 75% of stage 
IIA disease and only 56.25% of Stage I disease were 
found to have elevated CEA. 100% of cases in stage 
C1 & C2 of Duke’s staging system were found to have 
elevated CEA, 75% of cases in stage B2 and 64.28% of 
cases in stage B1 had elevated levels of CEA.  Serum 
concentrations of CEA were higher in cases with well 
differentiated adenocarcinoma (16.9%) followed by 
moderately differentiated (10.63%) and poorly 
differentiated (4.85%).The sensitivity of pre-operative 
CEA analysis was 73.33% and the positive predictive 
value was 100%.Post-operatively CEA was measured 
during follow-up after 3 months and 6months, to assess 
its efficacy in detecting early recurrence. None of the 
patients had elevated CEA within 3 months after 
surgery and none of them were found to have 
recurrence on evaluation with various imaging studies. 
7 cases had elevated CEA on follow-up at 6 months. 
Out of these 7 cases 6 were proven to have recurrence, 
1 local recurrence, 1 lung metastasis and 4 liver 
metastasis. 1case had peritoneal deposits on USG but 
CEA elevation was not found. Another case had 
elevated CEA but no recurrence was found on 
investigation. The cases with liver metastasis were 
subjected to hepatic segmentectomy. Patient with lung 
metastasis underwent chemotherapy and patient with 
local recurrence underwent radiation therapy. The 
sensitivity of serum CEA as an early indicator for 
recurrence was 85.71%, the specificity was 95.65%, 
positive predictive value was 85.71% and negative 
predictive value was 95.63%. 
Following are the results with respect to various 
parameters included in the study and have been 
compared with various other published studies. 
 
Comparison of pre-operative levels of CEA between studies 
 
Table 5: Comparison of pre-operative levels of CEA between studies 
 
 Takagawa R. et al % Taratino et al Present study % 
Raised pre-op CEA 14.4 22.4 73.33 
From table no. 5, we can see that in the present study pre-operative levels of CEA were elevated in 73.33% of cases. 
In studies by Takagawa et al [7] and Taratino et al [8] the pre-operative CEA levels were 14.4% and 22.4%. 
Sensitivity     85.71 % 
Specificity     95.65% 
Positive predictive value     85.71% 
Negative predictive value     95.63% 
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Comparison of CEA levels with respect to Duke’s staging 
Table 6: Comparison of CEA levels with respect to Duke’s staging 
 
Duke’s stage Harold J. et al % Present study % 
A 4 0 
B 26 66.66 
C 44 100 
D 65 - 
From Table no.6, we can see that the findings of this study are consistent with the study conducted by Harold. J et al 
[9] that the proportions of patients with elevated CEA increases with increase in the stage of the disease. In this 
study, Duke’s B stage had 66.66% patients with increase in CEA and 100% of cases in Duke’s stage D had elevated 
levels of CEA pre-operatively. 
 
Comparison of efficacy of CEA as a detector of early recurrence 
Table 7: Comparison of efficacy of CEA as a detector of early recurrence 
 Mc Call J.L et al Present study 
Sensitivity 58% 85.71% 
Specificity 93% 95.65% 
Positive predictive value 79% 85.71% 
Negative predictive value 83% 95.63% 
 In the present study, the efficacy of CEA to assess early recurrence post-operatively is in correlation with the study 
performed by Mc Call J.L et al [10] where the sensitivity was 58%, specificity was 93%, the positive predictive 
value was 79% and negative predictive value was 83%. 
 
Conclusion 
 
In this study serum CEA was an indicator for 
recurrence in 85.7% cases within 6 months. Based on 
high sensitivity and specificity we can conclude that 
CEA can be used effectively to detect early post-
operative recurrence in cases of colorectal cancer. 
Early detection followed by surgical or medical 
management of recurrence can improve the life 
expectancy and prognosis of cases of colorectal cancer. 
Limitations of this study is a small sample size and 
short period of study. 
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